Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195650 · ClinicalTrials.gov registry record · Phase 3
Long Term Open Label Continuation Study
A Phase 3 study of Rheumatoid Arthritis, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 846
- Enrollment target
- 20
- Study locations
NCT00195650: Completed Phase 3 study of Rheumatoid Arthritis, sponsored by Abbott.
NCT00195650 is a Phase 3 study of Rheumatoid Arthritis that has completed, run by Abbott. The registered enrollment target is 846 participants, below the 4,686-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00195650, a Phase 3 study of Rheumatoid Arthritis, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 846 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study was to assess the long-term safety and clinical efficacy following repeated administration of adalimumab in patients with rheumatoid arthritis.
Primary Outcome
ACR20 response criteria were: \>=20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes
Conditions Studied
Interventions
- BIOLOGICAL Adalimumab
Study Locations (20)
California
- Site Reference ID/Investigator# 66822 - Anaheim
- Site Reference ID/Investigator# 557 - La Jolla
- Site Reference ID/Investigator# 387 - Los Angeles
- Site Reference ID/Investigator# 555 - Los Angeles
- Site Reference ID/Investigator# 552 - Santa Barbara
- Site Reference ID/Investigator# 66864 - Santa Monica
- Site Reference ID/Investigator# 535 - Stanford
- Site Reference ID/Investigator# 3412 - Upland
- Site Reference ID/Investigator# 451 - Westlake Village
Alabama
- Site Reference ID/Investigator# 538 - Birmingham
- Site Reference ID/Investigator# 4111 - Birmingham
- Site Reference ID/Investigator# 4113 - Mobile
Colorado
- Site Reference ID/Investigator# 572 - Colorado Springs
- Site Reference ID/Investigator# 4109 - Denver
Connecticut
- Site Reference ID/Investigator# 541 - Danbury
- Site Reference ID/Investigator# 654 - Milford
Alaska
- Site Reference ID/Investigator# 408 - Anchorage
Arizona
- Site Reference ID/Investigator# 537 - Tucson
Delaware
- Site Reference ID/Investigator# 655 - Wilmington
Florida
- Site Reference ID/Investigator# 455 - Daytona Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 846 participants |
| Start Date | 2000-07 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
What the finished NCT00195650 record still lists
NCT00195650 is an interventional study that assigns participants to a tested intervention. The registered 846 participants enrollment target is mid-sized for trials with a published cap, below the 4,686-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Adalimumab is the first listed.
NCT00195650 names 20 study sites across 8 states, led by California, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT00195650 about?
NCT00195650 is a clinical study titled "Long Term Open Label Continuation Study". The purpose of the study was to assess the long-term safety and clinical efficacy following repeated administration of adalimumab in patients with rheumatoid arthritis.
What is the current status of trial NCT00195650?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 846 participants. The study started on 2000-07. Estimated completion is 2011-05.
What conditions does trial NCT00195650 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00195650?
The interventions under investigation include: Adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00195650?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00195650 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00195650's enrollment target sits among peer trials
846 27th of 197 higher than 171 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Ra-pro Pragmatic Trial
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02757859 · 845 participants · NA
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
- NCT07142408 · 848 participants · Phase 3
The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal
- NCT06747949 · 844 participants · Phase 3
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- NCT06439979 · 843 participants · NA
Rural Adult and Youth Sun Protection Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia